WASHINGTON – For the roughly 35 million Americans whose LDL levels remain dangerously high despite maximum statin doses, cardiologists have spent the past decade offering one alternative: a biweekly or monthly injection that most patients eventually abandon. Fear of needles accounts for some of that dropout. Cost and inconvenience account for more, and insurers have layered prior authorization requirements on top. The Food and Drug Administration moved Wednesday to give those patients a different path.
The agency approved enlicitide, sold under the brand name Lipfendra, an oral tablet from Merck that reduces LDL cholesterol by more than half in clinical trials, matching the performance of the injectable PCSK9 inhibitors that have defined the top tier of cholesterol treatment for a decade. It is the first pill of its class to reach that level of potency and the first oral PCSK9 inhibitor the agency has ever approved.
PCSK9 inhibitors work by blocking a protein that degrades the liver receptors responsible for clearing LDL from the blood. Injected versions, including evolocumab and alirocumab, became available in 2015 and can lower LDL by 50 to 60 percent, but their annual list prices near $5,000 and the need for self-injection have kept them out of reach for many patients who qualified. Studies have tracked those barriers: in the first year after the injectables launched, fewer than half of all approved prescriptions were actually filled. Oral candidates targeting the same pathway have repeatedly failed to replicate that potency in pill form, until now.
Lipfendra’s approval rests on two Phase 3 studies conducted under Merck’s CORALreef program. In the larger of the two, 2,904 patients with persistently elevated LDL on background statin therapy received enlicitide 20 milligrams daily or placebo. Those on the drug saw their LDL fall by 56 percent relative to placebo at week 24, according to the Merck press release. The result was measured against a surrogate endpoint rather than hard outcomes such as heart attacks or deaths.
The second trial enrolled 303 patients with heterozygous familial hypercholesterolemia, a genetic disorder that drives LDL to extreme levels from birth and accelerates the risk of early cardiovascular disease. In that group, enlicitide produced a 59 percent LDL reduction versus placebo. A larger cardiovascular study, the CORALreef Outcomes trial, is currently enrolling more than 14,500 participants and aims to determine whether those LDL reductions translate into fewer heart attacks and strokes. Results are not expected for several years.
Side effects were more pronounced in the familial hypercholesterolemia cohort than in the broader population studied. Diarrhea occurred in 7 percent of enlicitide patients versus 2 percent on placebo; dizziness in 9 percent versus 4 percent. Neither frequency prompted the FDA to require dose modifications, and rates in the larger CORALreef Lipids trial were lower. The drug’s safety profile across both studies was described as consistent with its mechanism and the patient populations enrolled.
Merck priced Lipfendra at $315 per month, placing it below the branded injectable PCSK9 drugs but well above the generic statins that most patients with elevated LDL already take. The lower price relative to injectables may ease some of the formulary resistance that delayed patient access when those earlier drugs launched. For cardiologists who monitor statin adherence in their practices, the more significant variable may be form: a once-daily pill is a different proposition from a self-injection that many patients decline regardless of clinical need or coverage.
“LIPFENDRA was designed to significantly lower LDL-C in the form of a convenient once-daily pill,” Dr. Dean Y. Li, president of Merck Research Laboratories, said in a company statement. The drug represents Merck’s most significant cardiology launch in more than a decade. Enlicitide was developed in-house as a macrocyclic peptide, a structural class that proved difficult for competitors pursuing the same target. The successful approval gives Merck a foothold in a cardiovascular market where injectable leaders have captured only a fraction of the patients who could theoretically benefit from PCSK9 blockade.
Formulary placement will shape the drug’s real-world reach more than any clinical result. Medicare’s prescription drug programs recently moved to cover GLP-1 weight-loss medicines for the first time, signaling some willingness to take on expensive new drug classes, but the agency has not yet issued guidance on Lipfendra. Commercial insurers have historically required prior authorization for PCSK9 inhibitors so stringent that many patients gave up before receiving the drug. Coverage decisions will be negotiated plan by plan over the coming months.
What Wednesday’s approval does not resolve is the central clinical question: whether Lipfendra prevents deaths. The FDA granted clearance based on LDL reduction, a well-validated surrogate supported by decades of evidence across multiple drug classes. Enlicitide’s effects on heart attacks, strokes, and cardiovascular mortality have not been established in a completed outcomes study. Cardiologists who prescribe it over the next several years will be reasoning from analogy rather than direct proof. The CORALreef Outcomes data will eventually close that gap. Until they do, 35 million patients with uncontrolled cholesterol have a new option, and a genuine clinical question that will take years to answer.
